Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $391K fell 10.1% year over year, behind the +180.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 37.2% from the prior quarter. Over 3 fiscal years it compounded at +0.4% a year.
Context
- Depreciation & amortization amounted to 11.0% of revenue in FY2025, down 14.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -10.1% toward the trailing-twelve-month pace of +180.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.34M USD
- Year-over-year change
- -24.4%
- 4-year CAGR
- +10.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.34M | -24.4% |
| FY2024 | 2024-12-31 | 1.77M | +51.6% |
| FY2023 | 2023-12-31 | 1.17M | -11.7% |
| FY2022 | 2022-12-31 | 1.32M | +44.7% |
| FY2021 | 2021-12-31 | 915K | — |
Depreciation & Amortization vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +180.4% is the highest of 11, against a peer median of -1.3%.
- Depreciation & amortization amounts to 9.2% of revenue for PRLD, versus a peer median of 29.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.81M USD | -13.0% | +11.0% | 3469.8% | |
| LTM Mar 2026 | $4.95M USD | +56.5% | +19.6% | 7.2% | |
| LTM Mar 2026 | $4.42M USD | +82.7% | +85.3% | 31.9% | |
| FY2025 | €3.22M EUR | -38.0% | +23.8% | 71.9% | |
| LTM Mar 2026 | $3.13M USD | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.84M USD | -8.0% | -25.0% | 10.1% | |
| LTM Mar 2026 | $1.53M USD | +180.4% | +0.4% | 9.2% | |
| LTM Mar 2026 | $531.13K USD | +15.1% | -4.3% | — | |
| LTM Mar 2026 | $334K USD | +5.4% | +13.8% | 1.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $263.36K USD | +65.0% | +17.8% | — |
| LTM Mar 2026 | $226K USD | -16.3% | +27.5% | 383.1% | |
| Peer median (excluding PRLD) | — | -1.3% | +15.8% | 29.9% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.93M | 25.14M | 25.62M | 21.35M | 11.91M |
| Change in Working Capital | 3.63M | 932K | (10.48M) | 4.22M | 28.41M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.9M | (347K) | (2.27M) | 3.31M | (3.92M) |
| Other Working Capital | (278K) | 1.28M | (8.21M) | 911K | 32.33M |
| Other Non-Cash Items | 2.69M | 4.31M | (1.54M) | (3.05M) | 1.53M |
| Operating Cash Flow | (83.53M) | (83.73M) | (107.06M) | (102.89M) | (56.3M) |
| Capital Expenditures | (2.32M) | (3.02M) | (3.51M) | (764K) | (67K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (261.48M) | (119.22M) | (221.63M) | (52.69M) | (100.87M) |
| Sales of Investments | 0 | 203.93M | 190.5M | 143.65M | 154.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (263.8M) | 81.69M | (34.65M) | 90.19M | 53.46M |
| Debt Repayment | 0 | 0 | 0 | (395K) | (208K) |
| Common Stock Issued | 161.42M | 815K | 135.73M | 329K | 25.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.47M | 0 | 664K | (54K) | (17K) |
| Financing Cash Flow | 164.9M | 815K | 136.4M | (120K) | 24.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (182.44M) | (1.22M) | (5.31M) | (12.82M) | 21.97M |
| Free Cash Flow | (85.85M) | (86.75M) | (110.58M) | (103.65M) | (56.37M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.